Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Inozyme Pharma, Inc. (INZY)

4.67   0.18 (4.01%) 09-27 11:13
Open: 4.73 Pre. Close: 4.49
High: 4.95 Low: 4.665
Volume: 299,121 Market Cap: 288(M)

Technical analysis

as of: 2023-09-27 10:47:38 AM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 6.09     One year: 7.12
Support: Support1: 4.42    Support2: 3.94
Resistance: Resistance1: 5.21    Resistance2: 6.09
Pivot: 4.55
Moving Average: MA(5): 4.55     MA(20): 4.63
MA(100): 5.48     MA(250): 3.83
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 47     %D(3): 43.7
RSI: RSI(14): 51.1
52-week: High: 7.32  Low: 0.99
Average Vol(K): 3-Month: 697 (K)  10-Days: 975 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INZY ] has closed below upper band by 29.3%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.84 - 4.87 4.87 - 4.9
Low: 3.88 - 3.91 3.91 - 3.94
Close: 4.44 - 4.49 4.49 - 4.53

Company Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 27 Sep 2023
Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by Needham ... - MarketBeat

Tue, 26 Sep 2023
Why Inozyme Pharma (INZY) Stock Is Trading Higher Today - Inozyme Pharma (NASDAQ:INZY) - Benzinga

Tue, 26 Sep 2023
Is Inozyme Pharma Inc (INZY) Stock a Good Value Tuesday? - InvestorsObserver

Tue, 26 Sep 2023
China and US Strengthen Economic Dialogue and Cooperation - Best Stocks

Sat, 09 Sep 2023
Wedbush Reaffirms Outperform Rating for Inozyme Pharma ... - MarketBeat

Wed, 06 Sep 2023
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 62 (M)
Shares Float 39 (M)
% Held by Insiders 0.9 (%)
% Held by Institutions 84.8 (%)
Shares Short 1,690 (K)
Shares Short P.Month 1,830 (K)

Stock Financials

EPS -1.42
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.27
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.5
Return on Equity (ttm) -53.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.15
Qtrly Earnings Growth 0
Operating Cash Flow -62 (M)
Levered Free Cash Flow -36 (M)

Stock Valuations

PE Ratio -3.35
PEG Ratio -0.3
Price to Book value 2.08
Price to Sales 0
Price to Cash Flow -4.72

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.